Klein Hersh Recruits CHRO for Disc Medicine
January 16, 2026 – Horsham, PA-based Klein Hersh, a search firm focused on the life sciences and healthcare industries, has placed Lisa Amaya Price as the new chief human resources officer of Disc Medicine, Inc. in Watertown, MA. “As we move towards commercialization, we have meaningfully increased hiring to support these efforts and Lisa will play a central role in building a strong, scalable organization by attracting, developing, and retaining exceptional talent across the business,” said John Quisel, president and CEO of Disc Medicine. “Her leadership will be instrumental as we continue to strengthen our capabilities and prepare the company for long-term success.”
Ms. Amaya Price brings more than 25 years of experience in human resources and organizational leadership, including at multiple commercial-stage companies. She joins Disc Medicine from Deciphera where she served as SVP and CHRO, helping lead the company’s integration into ONO Pharmaceuticals. Prior to this, Ms. Amaya Price was the chief people officer at LGC Group, a private-equity global life science tools company with over 4,000 employees worldwide.
Ms. Amaya Price was also a senior HR leader at Scholar Rock as well as Takeda Pharmaceuticals where she led organizational design and talent selection related to the acquisition of Shire Pharmaceuticals. Prior to Takeda, she spent eight years at Biogen, serving in various positions of increasing responsibility, including most recently senior director, human resources of R&D. Earlier in her career, she held human resource leadership positions at Interpublic Group, Inc., Metro International S.A., and American Financial Systems, Inc.
“I am excited to join Disc at this pivotal time for the company,” said Ms. Amaya Price. “The opportunity to help build and scale a team while preparing to deliver a much-needed therapy to patients with significant unmet needs is incredibly motivating. I look forward to partnering across the organization to support our people and culture as we enter this next phase of growth.”
Disc Medicine is a clinical stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. They are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis.
Related: Klein Hersh Assists Artios Pharma with CEO Search
Established in 1998, Klein Hersh is an executive search firm that partners with clients to deliver executive leaders for global pharmaceutical, biotech, and healthcare companies as well as operating businesses of PE and VC-backed investments. Noteworthy clients include Akero, Aktis Oncology, Apogee Therapeutics, ArchWell Health, Atlas Venture, Bain Capital Life Sciences, Biogen, Capital Rx, ConcertAI, CytoReason, Dispatch, Fairmount, Forbion, Foresite Capital, Frazier Healthcare Partners, Iambic, ITM, Koa Health, LifeMine, LongueVue Capital, Lyric, MacroHealth, McKesson, Moderna, Morningside, Odyssey Therapeutics, Oruka Therapeutics, Pacira Biosciences, Inc., Paragon Therapeutics, Posterity Health, Revolution Medicines, TPG, Transformation Capital, Treeline Biosciences, and Unlearn.
Newleos Therapeutics Search
Klein Hersh also recently assisted in the recruitment of Timothy Noyes as president and chief executive officer of biotechnology company Newleos Therapeutics in Boston, MA. Mr. Noyes succeeds David Donabedian, founding president and CEO of Newleos and executive partner at Longwood Fund, who will continue to serve the company in an advisory capacity. “When we founded Newleos, our mission was to build a leading company dedicated to transforming care for patients with serious psychiatric disorders,” said Christoph Westphal, executive chair of Newleos and founding partner of Longwood Fund. “Tim brings an exceptional track record of company building, fundraising, and advancing innovative therapies through early and late-stage development and commercialization. I have the utmost confidence in his ability to lead Newleos, advance our clinical programs, and guide the company into its next stage of growth.”
“On behalf of the entire board, I would like to recognize and thank David for his exceptional contributions as the founding president and CEO of Newleos,” continued Dr. Westphal. “David was instrumental in securing high-quality clinical assets from Roche that now comprise Newleos’ clinical pipeline, negotiating the license agreement for these assets, and building a world-class team.”
Mr. Noyes brings to Newleos more than 30 years of experience and a track record of successfully leading biopharmaceutical companies through critical phases of innovation and growth. He most recently served as CEO of Aerovate Therapeutics where, prior to its merger with Jade Biosciences, he guided the company through its successful IPO and advanced its lead clinical program for pulmonary arterial hypertension through a global Phase 2/3 trial.
Related: Klein Hersh Recruits CFO for Apogee Therapeutics
Contributed by Scott A. Scanlon, Editor-in-Chief and Dale M. Zupsansky, Executive Editor – Hunt Scanlon Media
